

Q3 conc.
expression sequence and a target gene which has relationship to production of the target substance and is linked downstream of the expression control sequence in a culture medium, and an intracellular concentration of an amino acid on which expression control by the expression control sequence depend, is changed to control expression of the target gene.--

IN THE SPECIFICATION

Please delete the Sequence Listing at pages 47-52 of the present application.

At page 57 (Abstract), after the last line, on the next page, please insert the Substitute Sequence Listing attached hereto.

REMARKS

Claims 1-13 are pending. Favorable consideration is respectfully requested.


The claims have been amended to remove multiple dependency. No new matter is believed to be introduced by the amendment to the claims.

Contents of the paper copy of the Substitute Sequence Listing and the computer-readable Sequence Listing filed herewith are identical. Support for all the sequences listed in the Substitute Sequence Listing can be found in the present application. No new matter is believed to be introduced by the submission of the Substitute Sequence Listing and the computer-readable Sequence Listing.

Applicants submit that this application is in condition for allowance. Early notice to this effect is earnestly solicited.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.



Norman F. Oblon
Attorney of Record
Registration No. 24,618

James J. Kelly, Ph.D.
Registration No. 41,504



22850

(703) 413-3000
Fax #: (703) 413-2220
NFO/JK

I:\atty\Twb\218897US-pr.wpd

MARKED-UP COPY

IN THE CLAIMS

Please amend the claims as follows.

- 5. (Amended) The expression control sequence according to claim 3 [or 4], wherein the number of the segments is 5.
6. (Amended) The expression control sequence according to [claims] Claim 3 [to 5], wherein the sequence of each segment of a part thereof and the sequence of the adjacent segment or a part thereof constitute an inverted repeat.
7. (Amended) The expression control sequence according to [claims] Claim 2 [to 6], wherein the p-independent terminator is capable of functioning in a bacterium belonging to the genus *Escherichia*, the genus *Salmonella*, or the genus *Serratia*.
9. (Amended) The expression control sequence according to claim 7 [or 8], which comprises five segments an1 to an5 in order form an upstream side, wherein the segments an1 and an2, and a conding region fo rthe leadre peptide are derived from a sequence of an attenuator of a tryptophan operon of *Escherichia coli*, the segments an4 and an5 are derived from a sequence of an attenuator of a histidine operon of *Escherichia coli*, and the segment an3 is derived from a combination of the sequences of the attenuator of the tryptophan operon and the histidine operon.

11. (Amended) A method for controlling an expression of a target gene, comprising the expression control sequence [as defined in any of the claims] according to Claim 1 [to 10], a promoter linked upstream of the expression control sequence and the target gene linked downstream of the expression control sequence in a culture medium, and changing an intracellular concentration of an amino acid on which expression control by the expression control sequence depend, to control expression of the target gene.

12. (Amended) A method for producing a target substance comprising the steps of cultivating a bacterium capable of producing the substance to produce the substance and collecting the substance,

wherein the bacterium harbors a DNA construct comprising the expression control sequence [as defined in any of the claims] according to Claim 1 [to 10], a promoter linked upstream of the expression sequence and a target gene which has relationship to production of the target substance and is linked downstream of the expression control sequence in a culture medium, and an intracellular concentration of an amino acid on which expression control by the expression control sequence depend, is changed to control expression of the target gene.--

IN THE SPECIFICATION

Please delete the Sequence Listing at pages 47-52 of the present application.

At page 57 (Abstract), after the last line, on the next page, please insert the Substitute Sequence Listing attached hereto.